Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty

Economou, Emmanuel; Tousoulis, Dimitris; Katinioti, Anastasia; Stefanadis, Christodoulos; Trikas, Athanasios; Pitsavos, Christos; Tentolouris, Costas; Toutouza, Marina; Toutouzas, Pavlos

doi:10.1016/s0167-5273(01)00454-5

Cited by 55 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to previous small case-control studies, [15][16][17] the present study population was heterogeneous and included patients treated with both invasive and conservative strategies.…”

Section: Discussionmentioning

confidence: 99%

“…12 In several small case-control studies, plasma MCP-1 levels were found to be highest among patients with acute coronary syndromes (ACS), intermediate among patients with stable coronary disease, and lowest among healthy control subjects; however, there was considerable overlap in MCP-1 levels between the groups. [15][16][17] No prospective data are available evaluating the relation between plasma MCP-1 levels and outcomes in patients with ACS.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes

et al. 2003

View full text Add to dashboard Cite

Background-Monocyte chemoattractant protein-1 (MCP-1) is a chemokine responsible for the recruitment of monocytes to sites of inflammation. MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction. After adjustment for differences in baseline characteristics, ECG changes, troponin I, and C-reactive protein, an MCP-1 level Ͼ75th percentile (corresponding to the 90th percentile in the healthy volunteers) was associated with an increased risk of death or myocardial infarction through 10 months of follow-up (adjusted hazard ratio, 1.53; 95% CI, 1.09 to 2.14; Pϭ0.01). Conclusions-In a large cohort of patients with acute coronary syndromes, an elevated baseline level of MCP-1 was associated both with traditional risk factors for atherosclerosis as well as an increased risk for death or myocardial infarction, independent of baseline variables. Because it appears to play a crucial role at multiple stages of atherosclerosis, MCP-1 is attractive as a surrogate biomarker and merits further study as a potential therapeutic target.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The Ϫ1328A/A promoter variant of this gene demonstrated a protective association with TVR. Economou et al 28 reported that eotaxin is elevated in plasma of patients with advanced atherosclerosis. The plasma level of eotaxin in their study rose in the first day after PCI and declined to baseline in the following 3 months.…”

Section: Ccl11mentioning

confidence: 99%

Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions

et al. 2005

View full text Add to dashboard Cite

Background-Restenosis is a negative effect of percutaneous coronary intervention (PCI). No clinical factors are available that allow good risk stratification. However, evidence exists that genetic factors are important in the restenotic process as well as in the process of inflammation, a pivotal factor in restenosis. Association studies have identified genes that may predispose to restenosis, but confirmation by large prospective studies is lacking. Our aim was to identify polymorphisms and haplotypes in genes involved in inflammatory pathways that predispose to restenosis. Methods and Results-The GENetic DEterminants of Restenosis (GENDER) project is a multicenter prospective study, including 3104 consecutive patients after successful PCI. Forty-eight polymorphisms in 34 genes in pathways possibly involved in the inflammatory process were analyzed. The 16Gly variant of the ␤ 2 -adrenergic receptor gave an increased risk of target vessel revascularization (TVR). The rare alleles of the CD14 gene (Ϫ260T/T), colony-stimulating factor 2 gene (117Thr/Thr), and eotaxin gene (Ϫ1328A/A) were associated with decreased risk of TVR. However, through the use of multiple testing corrections with permutation analysis, the probability of finding 4 significant markers by chance was 12%. Conclusions-Polymorphisms in 4 genes considered involved in the inflammatory reaction showed an association with TVR after PCI. Our results may contribute to the unraveling of the restenotic process. Given the explorative nature of this analysis, our results need to be replicated in other studies. (Circulation. 2005;112:2417-2425.)

show abstract

“…Eotaxin, an eosinophil-specific chemoattractant, is overexpressed in human atherosclerotic lesions, 14 and patients with coronary artery disease show higher circulating levels of eotaxin than healthy controls. 15,16 Accordingly, a nonconservative polymorphism in the eotaxin gene 17 and sequence variants affecting the eosinophil count 18 have recently been associated with an increased risk of myocardial infarction.…”

mentioning

confidence: 99%

Eosinophils: a new player in coronary atherosclerotic disease

Niccoli

Cosentino

2012

Hypertens Res

View full text Add to dashboard Cite

Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty

Cited by 55 publications

References 31 publications

Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes

Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes

Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions

Eosinophils: a new player in coronary atherosclerotic disease

Contact Info

Product

Resources

About